Losartan Legal and Patent Challenges: What Women Need to Know About FDA Approval, Labeling, and Safety

When Was Losartan FDA Approved and What Was the Patent Story?

Losartan received FDA approval on April 14, 1995, making it the first ARB cleared for use in the United States. Merck marketed it under the brand name Cozaar, and a fixed-dose combination with hydrochlorothiazide was approved the same year as Hyzaar.

The approval was significant for women's cardiovascular health. Hypertension affects roughly 45% of adult women in the United States, and older antihypertensive classes carried side-effect profiles that made adherence difficult. ARBs offered a new mechanism without the cough common to ACE inhibitors, a distinction that matters more for women, who report ACE-inhibitor cough at roughly twice the rate of men.

The Original Patent and Exclusivity Period

Merck held U.S. Patent No. 5,138,069 on the losartan molecule, along with additional patents covering the potassium salt formulation and manufacturing process. These patents, combined with a period of new chemical entity (NCE) exclusivity granted by the Hatch-Waxman Act, kept generic manufacturers out of the market for approximately 15 years after approval.

The Hatch-Waxman framework allows brand manufacturers to list patents in the FDA's Orange Book. Any generic applicant who challenges a listed patent must certify under Paragraph IV that the patent is invalid, unenforceable, or will not be infringed. Merck faced several such challenges, and the resulting litigation delayed generic entry.

Generic Entry in 2010

The first generic losartan potassium tablets entered the U.S. Market in April 2010, after the core compound patent expired. Within two years, the price of a 30-day supply fell by more than 80%, expanding access for women who had previously managed hypertension on higher-cost brand medication or gone undertreated due to cost.

Today, more than a dozen manufacturers hold approved ANDAs for losartan potassium. The FDA maintains a current list of all approved losartan products through Drugs@FDA.

What Does the Losartan Label Say? Key Points for Women

The current FDA-approved prescribing information for Cozaar runs to dozens of pages. Three sections are most relevant to women's health.

Black Box Warning: Pregnancy

The label carries a black box warning, the FDA's strongest safety alert. The exact regulatory text states:

"When pregnancy is detected, discontinue COZAAR as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus."

This applies from the moment of conception. Use during the second and third trimester is associated with fetal renal dysplasia, oligohydramnios, neonatal renal failure, skull hypoplasia, and death. Even first-trimester exposure carries risk, and no safe window has been established.

The practical consequence for any woman of reproductive age is clear: if you take losartan and are sexually active with potential for pregnancy, you need reliable contraception. If you stop contraception to try to conceive, losartan must be stopped first and an alternative antihypertensive substituted, ideally under the guidance of your prescriber and your OB-GYN or maternal-fetal medicine specialist.

Indicated Uses and Doses

The label approves losartan for:

• Hypertension in adults and pediatric patients aged 6 and older
• Reduction of stroke risk in patients with hypertension and left ventricular hypertrophy (LVH), though the label notes this benefit may not apply to Black patients based on trial data
• Nephropathy in patients with type 2 diabetes and elevated serum creatinine and proteinuria

The standard starting dose for hypertension is 50 mg once daily, with a range of 25 to 100 mg daily. For patients with volume depletion or hepatic impairment, the label recommends starting at 25 mg.

Side-Effect Profile and Women-Specific Considerations

The most common adverse events in trials were dizziness, upper respiratory infection, and nasal congestion. Hyperkalemia is a risk, particularly in women with chronic kidney disease or those using potassium-sparing diuretics, a combination common in PCOS management.

Unlike ACE inhibitors, ARBs do not increase bradykinin, which means the class is far less likely to cause the dry cough that disproportionately drives women off antihypertensive therapy. A meta-analysis found women discontinue ACE inhibitors due to cough at roughly twice the rate of men, making ARBs a particularly relevant option when cough limits adherence.

The LIFE Trial: The Evidence Base Behind the Stroke Indication

The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) trial, published in The Lancet in 2002, enrolled 9,193 patients with hypertension and electrocardiographic evidence of LVH. Participants were randomized to losartan-based or atenolol-based therapy.

Over a mean follow-up of 4.8 years, losartan reduced the composite primary endpoint of cardiovascular death, stroke, and myocardial infarction by 13% compared with atenolol (relative risk 0.87, 95% CI 0.77-0.98). The stroke reduction was particularly striking at 25% (relative risk 0.75, 95% CI 0.63-0.89), and this benefit was independent of blood pressure reduction, suggesting a direct effect of AT1 receptor blockade.

What LIFE Means for Women

The LIFE cohort was approximately 54% female, one of the higher female representation rates in a major cardiovascular trial of its era. Women in the losartan arm showed consistent benefit for stroke reduction, which is meaningful given that women face a higher lifetime stroke risk than men and are more likely to die or remain disabled after a stroke.

The trial also showed that the benefit over atenolol did not extend to Black patients, a finding preserved in the current label. For Black women with hypertension and LVH, the stroke-reduction indication may not apply, and thiazide diuretics or calcium channel blockers remain first-line per current guidelines.

Evidence Gaps the Trial Did Not Address

The LIFE trial did not stratify results by menopausal status, hormonal contraceptive use, or reproductive stage. Women using combined hormonal contraceptives, which raise blood pressure in a meaningful subset of users, were not analyzed separately. This is a genuine evidence gap. What happens to losartan's benefit-risk ratio in a woman who develops hypertension on the pill, or whose blood pressure rises in perimenopause as estrogen wanes, is extrapolated from general trial data, not directly studied in those subgroups. This is an honest limitation worth knowing before you and your clinician make a choice.

Recall History: Nitrosamine Impurities in Generic Losartan

Between 2018 and 2020, a wave of recalls hit the generic ARB market. The contaminant was N-nitrosodiethylamine (NDEA) and, in some lots, N-nitrosodimethylamine (NDMA), both probable human carcinogens according to FDA classification.

Losartan was caught in this sweep. Several manufacturers voluntarily recalled lots after FDA testing found NDEA at levels above the acceptable daily intake of 26.5 nanograms per day. The contamination traced back to a reaction involving a specific synthesis solvent used by certain API manufacturers, primarily based in China and India.

What the Recalls Mean for You

The FDA conducted extensive post-market surveillance through its Sentinel System and posted updated testing results at regular intervals. If you were taking a recalled lot at the time, your prescriber or pharmacist should have notified you. The risk from any single lot was considered low in absolute terms because exposure was time-limited, but the FDA took the position that there is no safe level of probable human carcinogens in medicine when avoidable.

For women in particular, any carcinogen exposure is worth discussing with your gynecologist, especially if you have a personal or family history of hormone-sensitive cancers. NDMA and NDEA do not appear to be hormone-mediated carcinogens, but the conversation is reasonable.

Current manufacturing standards require nitrosamine risk assessment for all drug products, per FDA guidance issued in September 2020. All losartan products on pharmacy shelves today should be manufactured under these updated controls.

Losartan Across Women's Life Stages

Reproductive Years (Ages 18-40)

If you are in your reproductive years and need an antihypertensive, losartan is an option for blood pressure control. The essential condition is reliable contraception. Options include long-acting reversible contraceptives (hormonal IUD, copper IUD, implant), or a combined hormonal method, with the caveat that combined hormonal contraceptives can themselves raise blood pressure in 5% of users. Your prescriber may prefer a progestin-only or non-hormonal method for this reason.

Women with PCOS who develop hypertension or metabolic-associated kidney stress may be considered for losartan, though direct PCOS-specific trials are limited. The insulin-sensitizing and anti-inflammatory properties sometimes attributed to AT1 blockade are mechanistically plausible but not confirmed in adequately powered PCOS-specific studies. Treat this as hypothesis, not established practice.

Trying to Conceive

Stop losartan before you stop contraception. This is not optional. Work with your cardiologist or internist to identify a pregnancy-safe antihypertensive before you begin trying. Labetalol, nifedipine, and methyldopa are the agents with the strongest safety record in pregnancy. The transition should be planned, not done in a panic after a positive test.

Pregnancy

Losartan is contraindicated. See the black box warning above. If you discover you are pregnant while on losartan, contact your prescriber the same day. The risk is highest in the second and third trimester, when the fetal renin-angiotensin system is active and kidneys are developing, but no trimester is confirmed safe.

Postpartum and Lactation

Human data on losartan transfer into breast milk are limited. Animal studies show transfer. The FDA label recommends against use during breastfeeding. LactMed, maintained by the National Institutes of Health, advises that safer alternatives exist and should be preferred. Nifedipine and labetalol are generally preferred in the postpartum lactating woman who needs blood pressure control.

Perimenopause and Post-Menopause

Blood pressure tends to rise in perimenopause as estrogen falls. The vasodilatory effects of estrogen on arterial walls diminish, vascular stiffness increases, and renin-angiotensin system activity may be relatively upregulated. ARBs are mechanistically well-suited to this physiology.

For post-menopausal women on hormone therapy (HT), there is no documented pharmacokinetic interaction between losartan and standard-dose estradiol or progesterone formulations. Blood pressure monitoring is still warranted when HT is initiated or adjusted, as some women see a small blood pressure rise with oral estrogen through hepatic angiotensinogen synthesis. Transdermal estradiol avoids this first-pass effect and is often preferred in women who already require tight blood pressure management.

Women with osteoporosis or at high fracture risk should note that losartan, like other ARBs, has been associated in observational data with modestly lower fracture rates compared with other antihypertensive classes. The mechanism may involve AT1 receptor blockade in osteoclasts. This data is observational and should not drive ARB selection, but it is a reasonable secondary consideration in a post-menopausal woman choosing among antihypertensive options.

Who Is Losartan Right For, and Who Should Avoid It?

Likely Right For You If:

• You have hypertension and are not pregnant or trying to conceive
• You previously stopped an ACE inhibitor due to cough
• You have hypertension with LVH (and are not Black, per LIFE trial data caveats)
• You have type 2 diabetes with proteinuria or early diabetic nephropathy
• You are post-menopausal with elevated cardiovascular risk and elevated blood pressure
• You have chronic kidney disease with proteinuria independent of diabetes

Likely Not Right For You If:

• You are pregnant or planning to become pregnant without first transitioning to a safer agent
• You are breastfeeding (safer options exist)
• You have bilateral renal artery stenosis
• You already have hyperkalemia (potassium above 5.0 mEq/L)
• You are also taking an ACE inhibitor or direct renin inhibitor (combination increases adverse renal and hyperkalemia risk without added cardiovascular benefit, per the ONTARGET trial findings)

Losartan and Drug Interactions Relevant to Women

Women are more likely than men to be prescribed multiple medications simultaneously, particularly combinations involving thyroid hormone, antidepressants, hormonal contraceptives, and antihypertensives.

Key interactions to know:

• NSAIDs (including ibuprofen, commonly used for dysmenorrhea or arthritis): NSAIDs blunt the blood-pressure-lowering effect of losartan and increase the risk of acute kidney injury. The combination should be limited and monitored.
• Potassium supplements or potassium-sparing diuretics: Combined use increases hyperkalemia risk. Women with PCOS who take spironolactone for acne or hair loss and then add an ARB need potassium monitoring.
• Lithium: ARBs reduce renal lithium clearance, raising lithium levels. Women on lithium for bipolar disorder need levels checked if losartan is added.
• Rifampin: This antibiotic induces CYP2C9, the enzyme responsible for converting losartan to its active metabolite E-3174. Rifampin co-administration reduces losartan's antihypertensive effect by approximately 35%.

Losartan is converted to E-3174 primarily by CYP2C9. Women who are CYP2C9 poor metabolizers (approximately 3-5% of the population) may have reduced conversion to active metabolite and attenuated blood pressure response, though this pharmacogenomic nuance is rarely tested in routine clinical practice.

Pregnancy and Lactation: The Full Picture

This section consolidates the pregnancy and lactation data required for any woman making an informed decision about losartan.

Pregnancy Category: Under the old FDA letter system, losartan was Category C in the first trimester and Category D in the second and third. The newer FDA labeling system (implemented for drugs approved after 2015, and progressively for older drugs) replaces letter categories with narrative summaries. The current Cozaar label under the Pregnancy and Lactation Labeling Rule (PLLR) states that use in the second and third trimester causes fetal harm and that human data show injury and death.

First trimester: Epidemiological studies have not consistently shown major congenital malformations from first-trimester ARB exposure, but some registries show a signal. The FDA considers no trimester safe.

Second and third trimester: The risk is mechanistic and well-documented. The fetal renin-angiotensin system is critical for kidney development. Blocking AT1 receptors during organogenesis and growth causes oligohydramnios (reduced amniotic fluid), which itself causes fetal limb contractures, craniofacial deformities, and pulmonary hypoplasia. Neonatal renal failure, sometimes irreversible, has been reported. Neonatal death has occurred.

What to do if you discover pregnancy while on losartan: Stop the medication the same day you get a positive test. Call your prescriber. Get an obstetric ultrasound to assess amniotic fluid volume as soon as possible, and follow the guidance of a maternal-fetal medicine specialist.

Lactation: Losartan transfers into rat milk. Human lactation data are absent, meaning no pharmacokinetic studies have been conducted in breastfeeding women. Because infant kidneys are immature and vulnerable to AT1 blockade, and because safer antihypertensives with adequate human lactation data exist, the standard clinical recommendation is to avoid losartan while breastfeeding. LactMed confirms this position.

Contraception requirement: Any woman of reproductive age on losartan should use effective contraception. This is not a soft recommendation. A copper IUD, hormonal IUD, or implant provides the highest reliability (greater than 99%) without blood pressure effects.